首页 > 最新文献

European annals of allergy and clinical immunology最新文献

英文 中文
A real-world characterization of a population with eosinophilic esophagitis: looking for severity biomarkers. 嗜酸性粒细胞食管炎患者的真实世界特征:寻找严重程度生物标记物。
IF 2.6 Q2 ALLERGY Pub Date : 2024-11-01 Epub Date: 2023-03-28 DOI: 10.23822/EurAnnACI.1764-1489.292
L Esteves Caldeira, R Limão, R Brás, E Pedro, C Costa

Summary: Background. Eosinophilic esophagitis (EoE) is an immune-mediated chronic esophageal disease, with frequent association with atopy. A vali-dated non/minimally invasive biomarker of disease severity has not been identified. We aimed to determine if sensitization to airborne and food allergens correlates with disease severity, and to evaluate the association between clinical and laboratory characteristics with the severity of EoE. Methods. Retrospective study of EoE patients observed in a differentiated center, 2009-2021. The association between patients' diagnosis age, disease duration before diagnosis, sensitization to airborne/food allergens, serum total IgE and peripheral blood eosinophil values and severe clinical disease (presence of symptoms with a significant impact on quality of life and/or ≥ 1 hospital admission due to EoE complications, namely severe dysphagia, food impaction or esophageal perforation) and histological severe disease (≥ 55 eos/hpf and/or microabscesses in esophageal biopsies) was evaluated. Results. 92 patients were observed, 83% male, 87% atopic. There was a mean delay in diagnosis of 4 years (range 0-31). 84% had aeroallergen sensitization and 71% food sensitization. Food impaction and dysphagia were the most frequent symptoms, and severe clinical disease was observed in 55%. Histologically, 37% had severity criteria. Patients with severe clinical disease had a significantly longer mean disease duration before diagnosis than patients without severe clinical disease (79 vs 15 months; p = 0.021). Patients who described food impaction were significantly older at time of diagnosis than those who have never had impaction (18 vs 9 years; p < 0.001). There was no significant association (p < 0.05) between sensitization, serum total IgE and peripheral blood eosinophil values and clinical or histological severity. Conclusions. An older age at diagnosis and a longer disease duration before diagnosis appear to be useful for pre-dicting EoE clinical severity. Despite having been demonstrated a high prevalence of allergic disease, the presence of sensitization to airborne and/ or food allergens do not seem to be useful for predicting clinical or histo-logical severity.

摘要:背景。嗜酸性粒细胞食管炎(EoE)是一种免疫介导的慢性食管疾病,常与过敏有关。目前尚未发现一种可确定疾病严重程度的非/微创生物标记物。我们旨在确定对空气传播和食物过敏原的致敏是否与疾病严重程度相关,并评估临床和实验室特征与食管炎严重程度之间的关联。研究方法对 2009-2021 年间在一家分化中心观察到的咽喉炎患者进行回顾性研究。研究评估了患者的诊断年龄、诊断前病程、对空气传播/食物过敏原的致敏程度、血清总 IgE 和外周血嗜酸性粒细胞值与严重临床疾病(出现对生活质量有重大影响的症状和/或因咽喉炎并发症(即严重吞咽困难、食物嵌塞或食管穿孔)入院≥1 次)和组织学严重疾病(食管活检中嗜酸性粒细胞≥55 eos/hpf 和/或微脓肿)之间的关联。结果共观察到 92 名患者,其中 83% 为男性,87% 为特应性患者。平均延迟诊断时间为 4 年(0-31 年不等)。84%的患者对空气过敏原过敏,71%的患者对食物过敏。食物嵌塞和吞咽困难是最常见的症状,55%的患者临床病情严重。从组织学角度来看,37%的患者达到了严重程度标准。有严重临床疾病的患者在确诊前的平均病程明显长于无严重临床疾病的患者(79 个月对 15 个月;P = 0.021)。描述过食物嵌塞的患者在确诊时的年龄明显大于从未有过嵌塞的患者(18 岁对 9 岁;P < 0.001)。致敏性、血清总 IgE 和外周血嗜酸性粒细胞值与临床或组织学严重程度之间无明显关联(p < 0.05)。结论确诊时年龄较大和确诊前病程较长似乎有助于预测肠易激综合征的临床严重程度。尽管过敏性疾病的发病率很高,但对空气传播的过敏原和/或食物过敏原的存在似乎对预测临床或组织学严重程度没有帮助。
{"title":"A real-world characterization of a population with eosinophilic esophagitis: looking for severity biomarkers.","authors":"L Esteves Caldeira, R Limão, R Brás, E Pedro, C Costa","doi":"10.23822/EurAnnACI.1764-1489.292","DOIUrl":"10.23822/EurAnnACI.1764-1489.292","url":null,"abstract":"<p><strong>Summary: </strong><b>Background.</b> Eosinophilic esophagitis (EoE) is an immune-mediated chronic esophageal disease, with frequent association with atopy. A vali-dated non/minimally invasive biomarker of disease severity has not been identified. We aimed to determine if sensitization to airborne and food allergens correlates with disease severity, and to evaluate the association between clinical and laboratory characteristics with the severity of EoE. <b>Methods.</b> Retrospective study of EoE patients observed in a differentiated center, 2009-2021. The association between patients' diagnosis age, disease duration before diagnosis, sensitization to airborne/food allergens, serum total IgE and peripheral blood eosinophil values and severe clinical disease (presence of symptoms with a significant impact on quality of life and/or ≥ 1 hospital admission due to EoE complications, namely severe dysphagia, food impaction or esophageal perforation) and histological severe disease (≥ 55 eos/hpf and/or microabscesses in esophageal biopsies) was evaluated. <b>Results.</b> 92 patients were observed, 83% male, 87% atopic. There was a mean delay in diagnosis of 4 years (range 0-31). 84% had aeroallergen sensitization and 71% food sensitization. Food impaction and dysphagia were the most frequent symptoms, and severe clinical disease was observed in 55%. Histologically, 37% had severity criteria. Patients with severe clinical disease had a significantly longer mean disease duration before diagnosis than patients without severe clinical disease (79 vs 15 months; p = 0.021). Patients who described food impaction were significantly older at time of diagnosis than those who have never had impaction (18 vs 9 years; p < 0.001). There was no significant association (p < 0.05) between sensitization, serum total IgE and peripheral blood eosinophil values and clinical or histological severity. <b>Conclusions.</b> An older age at diagnosis and a longer disease duration before diagnosis appear to be useful for pre-dicting EoE clinical severity. Despite having been demonstrated a high prevalence of allergic disease, the presence of sensitization to airborne and/ or food allergens do not seem to be useful for predicting clinical or histo-logical severity.</p>","PeriodicalId":11890,"journal":{"name":"European annals of allergy and clinical immunology","volume":" ","pages":"252-262"},"PeriodicalIF":2.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9199400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A survey on the association of seizure disorders with asthma and allergies in children. 关于癫痫发作与儿童哮喘和过敏症关系的调查。
IF 2.6 Q2 ALLERGY Pub Date : 2024-11-01 Epub Date: 2024-02-13 DOI: 10.23822/EurAnnACI.1764-1489.328
H Sadri, A Madanipour, N Toami, M Bakhtiari, H Montazerlotfelahi, E Zahmatkesh, A Zandifar, M Tavakol

Summary: Background. Little is known about the relationship between allergic diseases and seizure disorders including epilepsy. It is hypothesized that inflammation from allergic diseases may predispose children to seizures. The aim of this study is to investigate the frequency of seizure disorder in children with asthma and allergy. Methods. This is a cross-sectional survey study of parents of 1,300 children and adolescents under 20 years of age referred to the Allergy and Asthma Clinic of Imam Ali Hospital (Karaj) who were asked to complete a screening questionnaire for seizures in their children. Parents who reported any history of seizures in their children were contacted to answer a second in-depth questionnaire to determine more detail of type, triggers, and treatment of seizures. Results. A total of 705 males (62%) and 433 females (38%) participated in this study, with a mean and standard age of 6.62 ± 4.57 years. Among them, 70.6% had asthma, 15.2% had allergic rhinitis, 5.6% had atopic dermatitis, 3.5% had urticaria, 2.7% had food allergies, 1% had drug allergies, and 1.4% had other allergic diseases. Additionally, 88 patients (7.7%) had a history of doctor-diagnosed seizures, 57 patients (5%) had febrile convulsions, and 15 patients (1.31%) had idiopathic epilepsy. There was no significant relationship found between febrile convulsions, seizures, and epilepsy with the type of allergic diseases. However, a significant association was observed between the number of comorbid allergic diseases in patients with febrile convulsions (OR 1.4, 95%CI 1.07-1.83, p = 0.013). There was also an association between the epilepsy and comorbid allergic diseases number with an odds ratio OR 1.84, 95%CI 0.28-12, however the risk of epilepsy was increased by 0.84% but this increase was not significant. Regarding the relation between the number of allergic diseases in parents and idiopathic epilepsy in their children, a significant association was found only for mothers (OR 1.28, 95%CI 1.04-2.23, p = 0.024), but not for fathers (p > 0.05). Conclusions. Febrile convulsion is associated with the number of comorbid allergic diseases in children and the mother's number of allergic diseases is more related to idiopathic epilepsy in children than the father's.

摘要:背景。人们对过敏性疾病与癫痫等发作性疾病之间的关系知之甚少。本研究旨在调查哮喘和过敏性疾病患儿癫痫发作的频率。方法。对伊玛目阿里医院(Karaj)过敏和哮喘诊所转诊的 1300 名 20 岁以下儿童和青少年的父母进行横断面调查研究,要求他们填写儿童癫痫发作筛查问卷。我们还联系了报告其子女有癫痫发作史的家长,让他们回答第二份深入问卷,以确定癫痫发作的类型、诱因和治疗方法等更多细节。结果。共有 705 名男性(62%)和 433 名女性(38%)参加了此次研究,平均年龄(6.62±4.57)岁,标准年龄(6.62±4.57)岁。其中,70.6%患有哮喘,15.2%患有过敏性鼻炎,5.6%患有特应性皮炎,3.5%患有荨麻疹,2.7%患有食物过敏,1%患有药物过敏,1.4%患有其他过敏性疾病。此外,88 名患者(7.7%)有医生诊断的癫痫发作史,57 名患者(5%)有发热性惊厥,15 名患者(1.31%)有特发性癫痫。高热惊厥、癫痫发作和癫痫与过敏性疾病的类型没有明显的关系。然而,在发热性惊厥患者中,合并过敏性疾病的数量与发热性惊厥之间存在明显关联(OR=1.4,95% CI:1.07-1.83,P=0.013)。癫痫与合并过敏性疾病数量之间也存在关联,几率比OR=1.84,95% CI=0.28-12,然而癫痫的风险增加了0.84%,但这一增加并不明显。关于父母过敏性疾病数量与子女特发性癫痫之间的关系,只发现母亲有显著关联(OR=1.28,95% CI:1.04-2.23,P=0.024),而父亲没有显著关联(P>0.05)。结论发热性惊厥与儿童合并过敏性疾病的......数量有关,与父亲相比,母亲合并过敏性疾病的数量与儿童特发性癫痫的关系更大。
{"title":"A survey on the association of seizure disorders with asthma and allergies in children.","authors":"H Sadri, A Madanipour, N Toami, M Bakhtiari, H Montazerlotfelahi, E Zahmatkesh, A Zandifar, M Tavakol","doi":"10.23822/EurAnnACI.1764-1489.328","DOIUrl":"10.23822/EurAnnACI.1764-1489.328","url":null,"abstract":"<p><strong>Summary: </strong><b>Background.</b> Little is known about the relationship between allergic diseases and seizure disorders including epilepsy. It is hypothesized that inflammation from allergic diseases may predispose children to seizures. The aim of this study is to investigate the frequency of seizure disorder in children with asthma and allergy. <b>Methods.</b> This is a cross-sectional survey study of parents of 1,300 children and adolescents under 20 years of age referred to the Allergy and Asthma Clinic of Imam Ali Hospital (Karaj) who were asked to complete a screening questionnaire for seizures in their children. Parents who reported any history of seizures in their children were contacted to answer a second in-depth questionnaire to determine more detail of type, triggers, and treatment of seizures. <b>Results.</b> A total of 705 males (62%) and 433 females (38%) participated in this study, with a mean and standard age of 6.62 ± 4.57 years. Among them, 70.6% had asthma, 15.2% had allergic rhinitis, 5.6% had atopic dermatitis, 3.5% had urticaria, 2.7% had food allergies, 1% had drug allergies, and 1.4% had other allergic diseases. Additionally, 88 patients (7.7%) had a history of doctor-diagnosed seizures, 57 patients (5%) had febrile convulsions, and 15 patients (1.31%) had idiopathic epilepsy. There was no significant relationship found between febrile convulsions, seizures, and epilepsy with the type of allergic diseases. However, a significant association was observed between the number of comorbid allergic diseases in patients with febrile convulsions (OR 1.4, 95%CI 1.07-1.83, p = 0.013). There was also an association between the epilepsy and comorbid allergic diseases number with an odds ratio OR 1.84, 95%CI 0.28-12, however the risk of epilepsy was increased by 0.84% but this increase was not significant. Regarding the relation between the number of allergic diseases in parents and idiopathic epilepsy in their children, a significant association was found only for mothers (OR 1.28, 95%CI 1.04-2.23, p = 0.024), but not for fathers (p > 0.05). <b>Conclusions.</b> Febrile convulsion is associated with the number of comorbid allergic diseases in children and the mother's number of allergic diseases is more related to idiopathic epilepsy in children than the father's.</p>","PeriodicalId":11890,"journal":{"name":"European annals of allergy and clinical immunology","volume":" ","pages":"263-270"},"PeriodicalIF":2.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139722154","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Quantity increase and functional affinity/avidity decrease of anti-FcεRI and anti-IgE autoantibodies in chronic spontaneous urticaria. 慢性自发性荨麻疹患者体内抗FcεRI和抗IgE自身抗体的数量增加和功能亲和力/活性降低。
IF 2.6 Q2 ALLERGY Pub Date : 2024-11-01 Epub Date: 2023-12-13 DOI: 10.23822/EurAnnACI.1764-1489.320
L Joerg, N Mueller-Wirth, K Kammermann, O Stalder, W Pichler, O Hausmann

Summary: Background.Patients with autoimmune forms of chronic spontaneous ur-ticaria (aiCSU) exhibit autoantibodies against the high-affinity IgE recep-tor (FcεRI) and IgE. As the presence of these autoantibodies does not cor-relate with disease activity, the functional affinity/avidity may be relevant in aiCSU. This exploratory study aimed to characterize the quantity and avidity of autoantibodies against IgE and FcεRI over 6 months. Methods. The serum of 49 patients with CSU and 30 healthy control subjects was obtained at baseline and 6 months. Serum was analyzed by ELISA, to determine the quantity and avidity of anti-IgE and anti-FcεRI autoan-tibodies, and by basophil activation test (CU-BAT). Results. An increase in the quantity of anti-FcεRI and anti-IgE antibodies and a simultaneous decrease in avidity was found in all patients with CSU after 6 months: median anti-IgE increased from 6.7 ng/mL (IQR 5.1-12.5) to 23.8 ng/mL (IQR 12.3-121.5), p < 0.001, median anti-FcεRI from 52.4 ng/mL (IQR 26.3-111.4) to 129.5 ng/mL (IQR 73.7-253.7), p < 0.001. Me-dian anti-IgE avidity decreased from 75.8% (IQR 55.3-90.8) to 56.4% (IQR 30.6-76.2), p = 0.019 and median anti-FcεRI avidity from 75.1% (IQR 49.8-90.0) to 52.2 (IQR 38.2-60.1), p < 0.001. In contrast, the frequency of activated basophils did not change significantly over time. Surprisingly, autoantibody avidity did not correlate with basophil acti-vation. Conclusions. Both the quantity and avidity of anti-FcεRI and anti-IgE antibodies change over time, demonstrating that the CU-BAT is more suitable to diagnose aiCSU. In addition, the avidity of anti-FcεRI and anti-IgE antibodies do not correlate with CU-BAT and disease activ-ity, suggesting that further factors independent of anti-FcεRI and anti-IgE autoantibodies contribute to aiCSU.

摘要:背景。自身免疫性慢性自发性荨麻疹(aiCSU)患者会出现针对高亲和力 IgE 受体(FcεRI)和 IgE 的自身抗体。由于这些自身抗体的存在与疾病活动性无关,因此功能亲和力/无效性可能与aiCSU有关。这项探索性研究旨在分析 6 个月内针对 IgE 和 FcεRI 的自身抗体的数量和热敏性。研究方法49名CSU患者和30名健康对照组分别在基线和6个月时采集血清。采用酶联免疫吸附试验(ELISA)和嗜碱性粒细胞活化试验(CU-BAT)分析血清,以确定抗 IgE 和抗 FcεRI 自身抗体的数量和热敏性。结果显示6个月后,所有CSU患者的抗FcεRI和抗IgE抗体的数量都有所增加,同时抗体效价也有所下降:抗IgE抗体的中位数从6.7纳克/毫升(IQR 5.1-12.5)升至23.8纳克/毫升(IQR 12.3-121.5),P小于0.001;抗FcεRI中位数从52.4纳克/毫升(IQR 26.3-111.4)升至129.5纳克/毫升(IQR 73.7-253.7),P小于0.001。抗 IgE 阳性中位数从 75.8%(IQR 55.3-90.8)降至 56.4%(IQR 30.6-76.2),p=0.019;抗 FcεRI 阳性中位数从 75.1%(IQR 49.8-90.0)降至 52.2(IQR 38.2-60.1),p 小于 0.001。相比之下,活化嗜碱性粒细胞的频率并没有随着时间的推移而发生显著变化。令人惊讶的是,自身抗体的热敏性与嗜碱性粒细胞的活化并不相关。结论抗 FcεRI 抗体和抗 IgE 抗体的数量和效价都会随时间发生变化,这表明 CU-BAT 更适合诊断 aiCSU。此外,抗 FcεRI 和抗 IgE 抗体的热敏性与 CU-BAT 和疾病活动性并不相关,这表明在抗 FcεRI 和抗 IgE 自身抗体之外还有其他因素导致了 aiCSU。
{"title":"Quantity increase and functional affinity/avidity decrease of anti-FcεRI and anti-IgE autoantibodies in chronic spontaneous urticaria.","authors":"L Joerg, N Mueller-Wirth, K Kammermann, O Stalder, W Pichler, O Hausmann","doi":"10.23822/EurAnnACI.1764-1489.320","DOIUrl":"10.23822/EurAnnACI.1764-1489.320","url":null,"abstract":"<p><strong>Summary: </strong><b>Background.</b>Patients with autoimmune forms of chronic spontaneous ur-ticaria (aiCSU) exhibit autoantibodies against the high-affinity IgE recep-tor (FcεRI) and IgE. As the presence of these autoantibodies does not cor-relate with disease activity, the functional affinity/avidity may be relevant in aiCSU. This exploratory study aimed to characterize the quantity and avidity of autoantibodies against IgE and FcεRI over 6 months. <b>Methods.</b> The serum of 49 patients with CSU and 30 healthy control subjects was obtained at baseline and 6 months. Serum was analyzed by ELISA, to determine the quantity and avidity of anti-IgE and anti-FcεRI autoan-tibodies, and by basophil activation test (CU-BAT). <b>Results.</b> An increase in the quantity of anti-FcεRI and anti-IgE antibodies and a simultaneous decrease in avidity was found in all patients with CSU after 6 months: median anti-IgE increased from 6.7 ng/mL (IQR 5.1-12.5) to 23.8 ng/mL (IQR 12.3-121.5), p < 0.001, median anti-FcεRI from 52.4 ng/mL (IQR 26.3-111.4) to 129.5 ng/mL (IQR 73.7-253.7), p < 0.001. Me-dian anti-IgE avidity decreased from 75.8% (IQR 55.3-90.8) to 56.4% (IQR 30.6-76.2), p = 0.019 and median anti-FcεRI avidity from 75.1% (IQR 49.8-90.0) to 52.2 (IQR 38.2-60.1), p < 0.001. In contrast, the frequency of activated basophils did not change significantly over time. Surprisingly, autoantibody avidity did not correlate with basophil acti-vation. <b>Conclusions.</b> Both the quantity and avidity of anti-FcεRI and anti-IgE antibodies change over time, demonstrating that the CU-BAT is more suitable to diagnose aiCSU. In addition, the avidity of anti-FcεRI and anti-IgE antibodies do not correlate with CU-BAT and disease activ-ity, suggesting that further factors independent of anti-FcεRI and anti-IgE autoantibodies contribute to aiCSU.</p>","PeriodicalId":11890,"journal":{"name":"European annals of allergy and clinical immunology","volume":" ","pages":"271-280"},"PeriodicalIF":2.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138797917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Anaphylaxis biomarkers: present and future. 过敏性休克生物标志物:现状与未来。
IF 2.6 Q2 ALLERGY Pub Date : 2024-11-01 Epub Date: 2024-06-26 DOI: 10.23822/EurAnnACI.1764-1489.350
A Pampura, N Esakova, S Zimin, E Filippova

Summary: Anaphylaxis is a severe, rapidly developing, and life-threatening systemic hypersensitivity reaction. The diagnosis of anaphylaxis is primarily clinical. Numerous studies on the mechanisms and the biomarkers of the disease are initiated every year. The biomarkers of anaphylaxis may become an important tool for the diagnosis, prevention, repeated risk assessment, severity stratification, and new therapeutic strategies for treatment of the disease. Various immune and non-immune mediators produced and released by effector cell populations are currently considered as biomarkers of anaphylaxis. Here, we review the current data on potential biomarkers of anaphylaxis and the possibilities and perspectives for their use in future clinical practice.

摘要: 过敏性休克是一种严重、发展迅速、危及生命的全身性超敏反应。过敏性休克的诊断主要依靠临床。每年都有大量关于过敏性休克发病机制和生物标志物的研究。过敏性休克的生物标志物可能成为诊断、预防、重复风险评估、严重程度分层和治疗该疾病的新疗法的重要工具。目前,效应细胞群产生和释放的各种免疫和非免疫介质被认为是过敏性休克的生物标志物。在此,我们回顾了过敏性休克潜在生物标志物的现有数据以及在未来临床实践中使用这些生物标志物的可能性和前景。
{"title":"Anaphylaxis biomarkers: present and future.","authors":"A Pampura, N Esakova, S Zimin, E Filippova","doi":"10.23822/EurAnnACI.1764-1489.350","DOIUrl":"10.23822/EurAnnACI.1764-1489.350","url":null,"abstract":"<p><strong>Summary: </strong>Anaphylaxis is a severe, rapidly developing, and life-threatening systemic hypersensitivity reaction. The diagnosis of anaphylaxis is primarily clinical. Numerous studies on the mechanisms and the biomarkers of the disease are initiated every year. The biomarkers of anaphylaxis may become an important tool for the diagnosis, prevention, repeated risk assessment, severity stratification, and new therapeutic strategies for treatment of the disease. Various immune and non-immune mediators produced and released by effector cell populations are currently considered as biomarkers of anaphylaxis. Here, we review the current data on potential biomarkers of anaphylaxis and the possibilities and perspectives for their use in future clinical practice.</p>","PeriodicalId":11890,"journal":{"name":"European annals of allergy and clinical immunology","volume":" ","pages":"243-251"},"PeriodicalIF":2.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141450158","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy and tolerability of house dust mites subcutaneous immunotherapy with monomeric allergoid: an Italian multicenter study. 使用单体过敏原进行屋尘螨皮下免疫疗法的疗效和耐受性:一项意大利多中心研究。
IF 2.6 Q2 ALLERGY Pub Date : 2024-10-25 DOI: 10.23822/EurAnnACI.1764-1489.369
E Compalati, I Atzeni, S Cabras, P Fancello, R Longo, F Frati

Summary: Background. Subcutaneous immunotherapy is an effective treatment of respiratory allergy and allergoids offer a treatment option characterized by reduced IgE-binding properties to improve the safety profile. Purpose of this study was to investigate the efficacy and the safety of an injective monomeric allergoid in patients with moderate to severe persistent allergic rhinitis due to house dust mites. Methods. in a perspective, controlled, observational study a suspension of 0.70 mL at 10 BU/mL containing a mixture of carbamylated extract of Dermatophagoides was injected monthly for 12 months, following a 5-weeks build-up phase (0.10-0.20-0.30-0.50-0.70 mL weekly), to 58 patients (mean age 25.1 ± 12.7). A matching group of 60 patients (mean age 34.0 ± 14.2) was observed as control, and both groups were allowed to assume standard pharmacotherapy. After one year, changes from baseline in visual analogue scale for symptoms and drugs intake were compared; satisfaction rate was based on patients' and physicians' judgements. Results. In respect to baseline both groups showed an improvement in symptoms with a significant difference in favor of immunotherapy. Drugs intake was significantly lower in patients receiving injections. High level of agreement was found between doctors and patients on their rate of satisfaction. No serious reactions occurred, and at least a mild episodic local or systemic reaction was reported by a limited number of patients. Conclusions. In routine practice injective monomeric allergoid of house dust mites was safe and associated with a perceived significant clinical benefit in persistent rhinitis shown by objective and subjective outcomes.

摘要:背景。皮下免疫疗法是治疗呼吸道过敏症的有效方法,类过敏原提供了一种治疗选择,其特点是减少了 IgE 结合特性,从而提高了安全性。本研究的目的是调查注射单体类过敏原对中重度持续性屋尘螨过敏性鼻炎患者的疗效和安全性。方法:在一项透视、对照、观察性研究中,58 名患者(平均年龄为 25.1 ± 12.7 岁)每月注射一次 0.70 mL、浓度为 10 BU/mL 的悬浮液,其中含有氨甲酰化的 Dermatophagoides 提取物混合物,持续 12 个月,然后经过 5 周的积累阶段(每周注射 0.10-0.20-0.30-0.50-0.70 mL)。60 名患者(平均年龄为 34.0 ± 14.2)为对照组,两组患者均可接受标准药物治疗。一年后,比较视觉模拟量表中症状和药物摄入量与基线相比的变化;满意度基于患者和医生的判断。结果显示与基线相比,两组患者的症状都有所改善,但免疫疗法的效果明显优于前者。接受注射治疗的患者药物摄入量明显较低。医生和患者的满意度高度一致。没有出现严重反应,少数患者至少出现了轻微的局部或全身反应。结论在常规实践中,注射屋尘螨单体过敏原是安全的,而且从客观和主观结果来看,对顽固性鼻炎有明显的临床疗效。
{"title":"Efficacy and tolerability of house dust mites subcutaneous immunotherapy with monomeric allergoid: an Italian multicenter study.","authors":"E Compalati, I Atzeni, S Cabras, P Fancello, R Longo, F Frati","doi":"10.23822/EurAnnACI.1764-1489.369","DOIUrl":"https://doi.org/10.23822/EurAnnACI.1764-1489.369","url":null,"abstract":"<p><strong>Summary: </strong><b>Background.</b> Subcutaneous immunotherapy is an effective treatment of respiratory allergy and allergoids offer a treatment option characterized by reduced IgE-binding properties to improve the safety profile. Purpose of this study was to investigate the efficacy and the safety of an injective monomeric allergoid in patients with moderate to severe persistent allergic rhinitis due to house dust mites. <b>Methods.</b> in a perspective, controlled, observational study a suspension of 0.70 mL at 10 BU/mL containing a mixture of carbamylated extract of <i>Dermatophagoides</i> was injected monthly for 12 months, following a 5-weeks build-up phase (0.10-0.20-0.30-0.50-0.70 mL weekly), to 58 patients (mean age 25.1 ± 12.7). A matching group of 60 patients (mean age 34.0 ± 14.2) was observed as control, and both groups were allowed to assume standard pharmacotherapy. After one year, changes from baseline in visual analogue scale for symptoms and drugs intake were compared; satisfaction rate was based on patients' and physicians' judgements. <b>Results.</b> In respect to baseline both groups showed an improvement in symptoms with a significant difference in favor of immunotherapy. Drugs intake was significantly lower in patients receiving injections. High level of agreement was found between doctors and patients on their rate of satisfaction. No serious reactions occurred, and at least a mild episodic local or systemic reaction was reported by a limited number of patients. <b>Conclusions.</b> In routine practice injective monomeric allergoid of house dust mites was safe and associated with a perceived significant clinical benefit in persistent rhinitis shown by objective and subjective outcomes.</p>","PeriodicalId":11890,"journal":{"name":"European annals of allergy and clinical immunology","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2024-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142497430","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cost-effective allergy screening: a retrospective observational study. 具有成本效益的过敏筛查:一项回顾性观察研究。
IF 2.6 Q2 ALLERGY Pub Date : 2024-10-25 DOI: 10.23822/EurAnnACI.1764-1489.371
M D Martín-Martínez, G García-de la Rosa

Summary: Background. Allergies represent a substantial health concern affecting individuals across all age groups. Diagnostic screenings, such as phadiatop and phadiatop infant, are employed to identify specific IgE antibodies associated with allergic reactions. This study delves into the relationship between total IgE levels and screening test outcomes, with the objective of establishing a total IgE threshold capable of predicting the likelihood of negative results in these screenings. Methods. This retrospective observational study included adults and children under 15 years old who underwent total IgE tests in addition to phadiatop and phadiatop infant screenings from January 2018 to December 2022. Exclusion criteria were applied to patients with insufficient serum samples or those whose IgE determinations or screening tests had been invalidated according to standard laboratory protocols. Results. Data analysis uncovered a robust correlation between total IgE levels and screening test outcomes. Additionally, thresholds of 20 UI/mL and 28 UI/mL were pinpointed for total IgE levels, below which the likelihood of obtaining a positive result in phadiatop or phadiatop infant, respectively, significantly decreased. Conclusions. These findings present cost-effective strategies for healthcare practitioners by recommending the initial use of total IgE testing. Subsequently, reflex testing with phadiatop or phadiatop infant, depending on the IgE value, could be considered.

摘要:背景。过敏是影响各年龄段人群健康的一个重大问题。诊断性筛查(如 phadiatop 和 phadiatop 婴儿)用于确定与过敏反应相关的特异性 IgE 抗体。本研究深入探讨了总 IgE 水平与筛查结果之间的关系,目的是确定总 IgE 的阈值,以预测这些筛查出现阴性结果的可能性。研究方法这项回顾性观察研究纳入了2018年1月至2022年12月期间在法氏囊和法氏婴儿筛查之外接受总IgE检测的成人和15岁以下儿童。排除标准适用于血清样本不足的患者,或根据标准实验室规程IgE测定或筛查测试无效的患者。结果数据分析发现,总 IgE 水平与筛查测试结果之间存在密切联系。此外,总 IgE 水平的阈值分别为 20 UI/mL 和 28 UI/mL,低于这两个阈值,获得 phadiatop 或 phadiatop 婴儿阳性结果的可能性会显著降低。结论这些研究结果为医疗从业人员提供了具有成本效益的策略,建议首先使用总 IgE 检测。随后,根据 IgE 值的不同,可考虑使用 phadiatop 或 phadiatop 婴儿进行反射测试。
{"title":"Cost-effective allergy screening: a retrospective observational study.","authors":"M D Martín-Martínez, G García-de la Rosa","doi":"10.23822/EurAnnACI.1764-1489.371","DOIUrl":"https://doi.org/10.23822/EurAnnACI.1764-1489.371","url":null,"abstract":"<p><strong>Summary: </strong><b>Background</b>. Allergies represent a substantial health concern affecting individuals across all age groups. Diagnostic screenings, such as phadiatop and phadiatop infant, are employed to identify specific IgE antibodies associated with allergic reactions. This study delves into the relationship between total IgE levels and screening test outcomes, with the objective of establishing a total IgE threshold capable of predicting the likelihood of negative results in these screenings. <b>Methods</b>. This retrospective observational study included adults and children under 15 years old who underwent total IgE tests in addition to phadiatop and phadiatop infant screenings from January 2018 to December 2022. Exclusion criteria were applied to patients with insufficient serum samples or those whose IgE determinations or screening tests had been invalidated according to standard laboratory protocols. <b>Results</b>. Data analysis uncovered a robust correlation between total IgE levels and screening test outcomes. Additionally, thresholds of 20 UI/mL and 28 UI/mL were pinpointed for total IgE levels, below which the likelihood of obtaining a positive result in phadiatop or phadiatop infant, respectively, significantly decreased. <b>Conclusions</b>. These findings present cost-effective strategies for healthcare practitioners by recommending the initial use of total IgE testing. Subsequently, reflex testing with phadiatop or phadiatop infant, depending on the IgE value, could be considered.</p>","PeriodicalId":11890,"journal":{"name":"European annals of allergy and clinical immunology","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2024-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142497428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An overview of hidden food allergens: need for change to the priority food allergen lists? 隐性食物过敏原概述:是否需要修改优先食物过敏原清单?
IF 2.6 Q2 ALLERGY Pub Date : 2024-10-25 DOI: 10.23822/EurAnnACI.1764-1489.370
G Parrinello, D E Fontana, D Villalta

Summary: Many food allergens not actually included in the European priority list of allergenic foods have the potential to cause severe allergic reactions and could escape correct identification and behave as "hidden allergens". Moreover, the adoption in recent years of novel diets based on plant products and new sustainable foods or the use of specific food additives have contributed to the onset of new emerging allergens of public health importance. The knowledge of hidden allergens is important both for physicians and for patients to improve the prevention, diagnosis and treatment of food allergies, in order to decrease eventual improper diagnosis of idiopathic anaphylaxis. In this review, the characteristics of the most frequent hidden allergens and their diagnostic tools are described. A detailed history with a careful review of the ingredient lists, an understanding of possible cross-reactions or contaminations with other foods, together with an allergological evaluation consisting of in vivo or in vitro tests and, where necessary, an oral food challenge, are recommended for the successful identification of the culprit allergen. In future, it will be very important to implement these diagnostic tools, especially in the field of molecular allergology, and reporting allergens on labels should become mandatory.

摘要:许多实际上未列入欧洲致敏食品优先清单的食物过敏原都有可能引起严重过敏反应,并有可能逃脱正确识别,成为 "隐性过敏原"。此外,近年来基于植物产品的新型饮食和新的可持续食品的采用或特定食品添加剂的使用,也导致了具有公共卫生重要性的新出现的过敏原的出现。了解隐藏的过敏原对于医生和患者改进食物过敏的预防、诊断和治疗都很重要,这样才能减少特发性过敏性休克的不当诊断。本综述介绍了最常见的隐性过敏原的特征及其诊断工具。为了成功识别致敏原,建议详细询问病史并仔细查看配料表,了解可能与其他食物发生的交叉反应或污染,同时进行过敏学评估,包括体内或体外试验,必要时进行口服食物挑战。今后,采用这些诊断工具,特别是在分子过敏学领域,将是非常重要的,在标签上报告过敏原应成为强制性的。
{"title":"An overview of hidden food allergens: need for change to the priority food allergen lists?","authors":"G Parrinello, D E Fontana, D Villalta","doi":"10.23822/EurAnnACI.1764-1489.370","DOIUrl":"https://doi.org/10.23822/EurAnnACI.1764-1489.370","url":null,"abstract":"<p><strong>Summary: </strong>Many food allergens not actually included in the European priority list of allergenic foods have the potential to cause severe allergic reactions and could escape correct identification and behave as \"hidden allergens\". Moreover, the adoption in recent years of novel diets based on plant products and new sustainable foods or the use of specific food additives have contributed to the onset of new emerging allergens of public health importance. The knowledge of hidden allergens is important both for physicians and for patients to improve the prevention, diagnosis and treatment of food allergies, in order to decrease eventual improper diagnosis of idiopathic anaphylaxis. In this review, the characteristics of the most frequent hidden allergens and their diagnostic tools are described. A detailed history with a careful review of the ingredient lists, an understanding of possible cross-reactions or contaminations with other foods, together with an allergological evaluation consisting of <i>in vivo</i> or <i>in vitro</i> tests and, where necessary, an oral food challenge, are recommended for the successful identification of the culprit allergen. In future, it will be very important to implement these diagnostic tools, especially in the field of molecular allergology, and reporting allergens on labels should become mandatory.</p>","PeriodicalId":11890,"journal":{"name":"European annals of allergy and clinical immunology","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2024-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142497427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Different clinical phenotypes in common variable immunodeficiency. 常见变异性免疫缺陷病的不同临床表型。
IF 2.6 Q2 ALLERGY Pub Date : 2024-10-14 DOI: 10.23822/EurAnnACI.1764-1489.368
M Ribeiro Rodero, M Benevides, B M Nascimento, H de Almeida Secchi, P Roxo-Junior

Summary: Background. We aimed to describe the clinical heterogeneity (infectious and noninfectious manifestations) and the impact of immunoglobulin replacement therapy on the reduction of infections in patients given a diagnosis of common variable immunodeficiency. Methods. This was a descriptive case series study. Medical charts were retrospectively reviewed based on demographics, clinical presentation, immunoglobulin replacement therapy and laboratory findings at diagnosis. Results. Thirty six common variable immunodeficiency patients were enrolled. Nineteen of them were male (53%). The median age at onset of symptoms was 8 years and at common variable immunodeficiency diagnosis was 19 years. Family history for immunodeficiency was observed in 2 patients (5%). Recurrent infections were present in 35 patients (97%) and they were the first clinical manifestations in 31 patients (86%). Respiratory infections were the most frequent, followed by gastrointestinal infections. Noninfectious manifestations were present in 32 patients (89%), including bronchopulmonary disease, allergy, autoimmunity, lymphoproliferation, gastrointestinal disorders and malignancy. Chronic pulmonary disease and lymphoproliferation were the most common. There was an important reduction of infections 1 year after begining immunoglobulin replacement therapy, mainly pneumonia and sinusitis. Conclusions. Although the diagnosis of common variable immunodeficiency has improved over the last decade, many patients are still being referred and diagnosed late. Physicians must recognize that both infectious and noninfectious manifestations can be the initial signs of common variable immunodeficiency and are very common in these patients. Immunoglobulin replacement therapy significantly reduces respiratory infections.

摘要:背景。我们旨在描述临床异质性(感染性和非感染性表现)以及免疫球蛋白替代疗法对减少常见可变免疫缺陷患者感染的影响。研究方法这是一项描述性病例系列研究。根据人口统计学、临床表现、免疫球蛋白替代疗法和诊断时的实验室结果对病历进行回顾性分析。结果。共纳入 36 名常见变异性免疫缺陷患者。其中 19 人为男性(53%)。发病年龄中位数为 8 岁,确诊常见可变免疫缺陷症的年龄中位数为 19 岁。2名患者(5%)有免疫缺陷家族史。35名患者(97%)出现反复感染,31名患者(86%)的首发临床表现为反复感染。最常见的是呼吸道感染,其次是胃肠道感染。32名患者(89%)出现非感染性表现,包括支气管肺部疾病、过敏、自身免疫、淋巴增生、胃肠道疾病和恶性肿瘤。慢性肺部疾病和淋巴增生最为常见。开始免疫球蛋白替代疗法一年后,感染病例明显减少,主要是肺炎和鼻窦炎。结论。虽然常见变异性免疫缺陷症的诊断在过去十年中有所改善,但仍有许多患者被转诊和诊断过晚。医生必须认识到,感染性和非感染性表现都可能是普通可变免疫缺陷症的初期症状,而且在这些患者中非常常见。免疫球蛋白替代疗法可显著减少呼吸道感染。
{"title":"Different clinical phenotypes in common variable immunodeficiency.","authors":"M Ribeiro Rodero, M Benevides, B M Nascimento, H de Almeida Secchi, P Roxo-Junior","doi":"10.23822/EurAnnACI.1764-1489.368","DOIUrl":"https://doi.org/10.23822/EurAnnACI.1764-1489.368","url":null,"abstract":"<p><strong>Summary: </strong><b>Background.</b> We aimed to describe the clinical heterogeneity (infectious and noninfectious manifestations) and the impact of immunoglobulin replacement therapy on the reduction of infections in patients given a diagnosis of common variable immunodeficiency. <b>Methods.</b> This was a descriptive case series study. Medical charts were retrospectively reviewed based on demographics, clinical presentation, immunoglobulin replacement therapy and laboratory findings at diagnosis. <b>Results.</b> Thirty six common variable immunodeficiency patients were enrolled. Nineteen of them were male (53%). The median age at onset of symptoms was 8 years and at common variable immunodeficiency diagnosis was 19 years. Family history for immunodeficiency was observed in 2 patients (5%). Recurrent infections were present in 35 patients (97%) and they were the first clinical manifestations in 31 patients (86%). Respiratory infections were the most frequent, followed by gastrointestinal infections. Noninfectious manifestations were present in 32 patients (89%), including bronchopulmonary disease, allergy, autoimmunity, lymphoproliferation, gastrointestinal disorders and malignancy. Chronic pulmonary disease and lymphoproliferation were the most common. There was an important reduction of infections 1 year after begining immunoglobulin replacement therapy, mainly pneumonia and sinusitis. <b>Conclusions.</b> Although the diagnosis of common variable immunodeficiency has improved over the last decade, many patients are still being referred and diagnosed late. Physicians must recognize that both infectious and noninfectious manifestations can be the initial signs of common variable immunodeficiency and are very common in these patients. Immunoglobulin replacement therapy significantly reduces respiratory infections.</p>","PeriodicalId":11890,"journal":{"name":"European annals of allergy and clinical immunology","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2024-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142461005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sensitisation to Lep d 2- Lepidoglyphus destructor allergy in asthma and rhinitis. 哮喘和鼻炎患者对 Lep d 2- Lepidoglyphus destructor 的过敏反应。
IF 2.6 Q2 ALLERGY Pub Date : 2024-10-11 DOI: 10.23822/EurAnnACI.1764-1489.367
F Matos Semedo, E Tomaz, C Martins, L Taborda-Barata, F Inácio

Summary: Background. Mites are responsible for allergic diseases, such as asthma and rhinitis, in nearly 1.5% of the world population. It is known that nowadays, besides House Dust Mites (HDM), Storage Mites (SM) are important sensitisers in urban non-occupational dwellings, predominantly in the Mediterranean area. The main objective of our study was to analyse the clinical relevance of the most prevalent SM, Lepidoglyphus destructor, by assessing the relationship between sensitisation to the major molecular allergen Lep d 2 and allergic respiratory disease phenotype in an urban population monosensitised to this molecular allergen. Methods. Cross-sectional study which included consecutive patients evaluated in our Allergy Department between 2012 and 2018, from urban non-occupational setting, with rhinitis and/or asthma, perennial symptoms and proven sensitisation to SM Lep d 2, tested using ImmunoCAP Immuno Solid-phase Allergen Chip (ISAC) technology, which detects 112 allergens. Results. A total of 37 allergic patients were included (23 female), aged 20.1 ± 12.8, min-max 5-58 years-old. The molecular sensitisation profile showed 18.9% of L. destructor mite monosensitised patients, having only sIgE to Lep d 2. This subset of patients mainly had allergic rhinitis, with 28.6% also being asthmatic. Regarding severity, most patients showed a persistent moderate phenotype of respiratory disease. The mean value of Lep d 2 sIgE was 8.3 ± 9.8 ISU-E, lower than in mite polysensitised patients (21.7 ± 21.5, p = 0.049). Conclusions. Our proof-of-concept study focused on Lep d 2 monosensitisation, showed that SM may have clinical relevance in perennial allergic asthma and rhinitis, and should be taken into account when assessing and treating allergic respiratory disease. Conclusions. The present survey demonstrated that Italian primary care pediatricians accomplish ARIA guidelines and adapt treatment on the basis of the intensity of symptoms. Corticosteroids and antihistamines are the most common prescribed medications. Nasal lavages are also popular.

摘要:背景。螨虫是导致过敏性疾病(如哮喘和鼻炎)的罪魁祸首,全世界有近 1.5%的人患有这种疾病。众所周知,如今除了屋尘螨(HDM)之外,储藏螨(SM)也是城市非职业性住宅(主要在地中海地区)中的重要致敏原。我们研究的主要目的是通过评估对主要分子过敏原 Lep d 2 的致敏与对该分子过敏原单敏的城市人群中过敏性呼吸道疾病表型之间的关系,分析最常见的储螨--破坏螨的临床相关性。研究方法横断面研究纳入了2012年至2018年期间在我院过敏科接受评估的连续患者,这些患者来自城市非职业环境,患有鼻炎和/或哮喘,常年出现症状,并已证实对SM Lep d 2过敏,使用可检测112种过敏原的ImmunoCAP免疫固相过敏原芯片(ISAC)技术进行检测。结果。共纳入 37 名过敏症患者(23 名女性),年龄为 20.1 ± 12.8 岁,最小-最大年龄为 5-58 岁。分子致敏图谱显示,18.9%的破坏螨患者为单敏患者,只对 Lep d 2 产生 sIgE。这部分患者主要患有过敏性鼻炎,其中 28.6% 还患有哮喘。就严重程度而言,大多数患者的呼吸道疾病表现为持续的中度表型。Lep d 2 sIgE 的平均值为 8.3 ± 9.8 ISU-E,低于螨虫多敏患者(21.7 ± 21.5,p = 0.049)。结论我们的概念验证研究侧重于 Lep d 2 单敏化,结果表明 SM 可能对常年性过敏性哮喘和鼻炎有临床意义,在评估和治疗过敏性呼吸道疾病时应加以考虑。结论。本调查表明,意大利初级保健儿科医生会执行 ARIA 指南,并根据症状强度调整治疗方法。皮质类固醇和抗组胺药是最常见的处方药。鼻腔灌洗也很受欢迎。
{"title":"Sensitisation to Lep d 2- Lepidoglyphus destructor allergy in asthma and rhinitis.","authors":"F Matos Semedo, E Tomaz, C Martins, L Taborda-Barata, F Inácio","doi":"10.23822/EurAnnACI.1764-1489.367","DOIUrl":"https://doi.org/10.23822/EurAnnACI.1764-1489.367","url":null,"abstract":"<p><strong>Summary: </strong><b>Background.</b> Mites are responsible for allergic diseases, such as asthma and rhinitis, in nearly 1.5% of the world population. It is known that nowadays, besides House Dust Mites (HDM), Storage Mites (SM) are important sensitisers in urban non-occupational dwellings, predominantly in the Mediterranean area. The main objective of our study was to analyse the clinical relevance of the most prevalent SM, <i>Lepidoglyphus destructor</i>, by assessing the relationship between sensitisation to the major molecular allergen Lep d 2 and allergic respiratory disease phenotype in an urban population monosensitised to this molecular allergen. <b>Methods.</b> Cross-sectional study which included consecutive patients evaluated in our Allergy Department between 2012 and 2018, from urban non-occupational setting, with rhinitis and/or asthma, perennial symptoms and proven sensitisation to SM Lep d 2, tested using ImmunoCAP Immuno Solid-phase Allergen Chip (ISAC) technology, which detects 112 allergens. <b>Results.</b> A total of 37 allergic patients were included (23 female), aged 20.1 ± 12.8, min-max 5-58 years-old. The molecular sensitisation profile showed 18.9% of <i>L. destructor</i> mite monosensitised patients, having only sIgE to Lep d 2. This subset of patients mainly had allergic rhinitis, with 28.6% also being asthmatic. Regarding severity, most patients showed a persistent moderate phenotype of respiratory disease. The mean value of Lep d 2 sIgE was 8.3 ± 9.8 ISU-E, lower than in mite polysensitised patients (21.7 ± 21.5, p = 0.049). <b>Conclusions.</b> Our proof-of-concept study focused on Lep d 2 monosensitisation, showed that SM may have clinical relevance in perennial allergic asthma and rhinitis, and should be taken into account when assessing and treating allergic respiratory disease. <b>Conclusions</b>. The present survey demonstrated that Italian primary care pediatricians accomplish ARIA guidelines and adapt treatment on the basis of the intensity of symptoms. Corticosteroids and antihistamines are the most common prescribed medications. Nasal lavages are also popular.</p>","PeriodicalId":11890,"journal":{"name":"European annals of allergy and clinical immunology","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2024-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142399744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Allergic rhinitis management: a survey on Italian primary care pediatricians. 过敏性鼻炎管理:意大利初级儿科医生调查。
IF 2.6 Q2 ALLERGY Pub Date : 2024-10-11 DOI: 10.23822/EurAnnACI.1764-1489.365
M Miraglia Del Giudice, C Indolfi, G L Marseglia, M A Tosca, A M Zicari, G Ciprandi

Summary: Background. Allergic rhinitis (AR) is a widespread condition. The Italian Society of Pediatric Allergology and Immunology (SIAIP) promoted an initiative to update the knowledge on AR in children and adolescents. The present survey directly addressed primary care pediatricians, thus reflecting the real-world management of AR in children and adolescents. The aim was to investigate common practice in managing AR children. Methods. A panel of experts drafted a series of questions concerning the practical management of children with AR in clinical practice. The questionnaire was administered to a large sample of primary care pediatricians (864). Results. 864 primary care pediatricians participated to the survey. Each pediatrician on average follows 94 children with AR; globally 81,231 children. More than 70% of participants follow ARIA guidelines. Accordingly, 42% of children have mild AR and 58% moderate/severe. Asthma, conjunctivitis and adenoid hypertrophy are the most common comorbidity. Most pediatricians autonomously follow their patients. The intensity of treatment (use of medication) is directly proportional to the symptom severity.  Intranasal corticosteroids are the most common medication used followed by oral antihistamines and nasal lavages (with hypertonic or isotonic solution). Up to 20% of participants prescribe the fixed association topical corticosteroids plus antihistamine. Conclusions. The present survey demonstrated that Italian primary care pediatricians accomplish ARIA guidelines and adapt treatment on the basis of the intensity of symptoms. Corticosteroids and antihistamines are the most common prescribed medications. Nasal lavages are also popular.

摘要:背景。过敏性鼻炎(AR)是一种普遍存在的疾病。意大利儿科过敏与免疫学学会(SIAIP)发起了一项倡议,旨在更新儿童和青少年对过敏性鼻炎的认识。本调查直接针对初级保健儿科医生,因此反映了儿童和青少年 AR 的实际管理情况。目的是调查管理 AR 儿童的常见做法。调查方法专家小组起草了一系列有关临床实践中 AR 儿童实际管理的问题。该问卷调查的对象是大样本的初级保健儿科医生(864 人)。结果。864 名初级儿科医生参与了调查。每位儿科医生平均跟踪 94 名 AR 患儿;全球共跟踪 81,231 名患儿。超过 70% 的参与者遵循 ARIA 指南。因此,42%的儿童患有轻度AR,58%患有中度/重度AR。哮喘、结膜炎和腺样体肥大是最常见的合并症。大多数儿科医生都会对患者进行自主随访。治疗(用药)的强度与症状的严重程度成正比。 鼻内皮质类固醇是最常用的药物,其次是口服抗组胺药和洗鼻(使用高渗或等渗溶液)。多达 20% 的参与者会处方固定联用的局部皮质类固醇加抗组胺药。结论。本次调查表明,意大利初级保健儿科医生执行了 ARIA 指南,并根据症状强度调整了治疗方法。皮质类固醇和抗组胺药是最常见的处方药。鼻腔灌洗也很受欢迎。
{"title":"Allergic rhinitis management: a survey on Italian primary care pediatricians.","authors":"M Miraglia Del Giudice, C Indolfi, G L Marseglia, M A Tosca, A M Zicari, G Ciprandi","doi":"10.23822/EurAnnACI.1764-1489.365","DOIUrl":"https://doi.org/10.23822/EurAnnACI.1764-1489.365","url":null,"abstract":"<p><strong>Summary: </strong><b>Background.</b> Allergic rhinitis (AR) is a widespread condition. The Italian Society of Pediatric Allergology and Immunology (SIAIP) promoted an initiative to update the knowledge on AR in children and adolescents. The present survey directly addressed primary care pediatricians, thus reflecting the real-world management of AR in children and adolescents. The aim was to investigate common practice in managing AR children. <b>Methods.</b> A panel of experts drafted a series of questions concerning the practical management of children with AR in clinical practice. The questionnaire was administered to a large sample of primary care pediatricians (864). <b>Results.</b> 864 primary care pediatricians participated to the survey. Each pediatrician on average follows 94 children with AR; globally 81,231 children. More than 70% of participants follow ARIA guidelines. Accordingly, 42% of children have mild AR and 58% moderate/severe. Asthma, conjunctivitis and adenoid hypertrophy are the most common comorbidity. Most pediatricians autonomously follow their patients. The intensity of treatment (use of medication) is directly proportional to the symptom severity.  Intranasal corticosteroids are the most common medication used followed by oral antihistamines and nasal lavages (with hypertonic or isotonic solution). Up to 20% of participants prescribe the fixed association topical corticosteroids plus antihistamine. <b>Conclusions</b>. The present survey demonstrated that Italian primary care pediatricians accomplish ARIA guidelines and adapt treatment on the basis of the intensity of symptoms. Corticosteroids and antihistamines are the most common prescribed medications. Nasal lavages are also popular.</p>","PeriodicalId":11890,"journal":{"name":"European annals of allergy and clinical immunology","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2024-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142399734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
European annals of allergy and clinical immunology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1